- Home
- MIST vs CNTB Comparison
MIST vs CNTB Comparison
Compare MIST & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CNTB
- Stock Information
- Founded
- MIST 2003
- CNTB 2012
- Country
- MIST Canada
- CNTB United States
- Employees
- MIST N/A
- CNTB N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- CNTB Health Care
- Exchange
- MIST Nasdaq
- CNTB Nasdaq
- Market Cap
- MIST 81.5M
- CNTB 68.5M
- IPO Year
- MIST N/A
- CNTB 2021
- Fundamental
- Price
- MIST $1.43
- CNTB $1.17
- Analyst Decision
- MIST Strong Buy
- CNTB Strong Buy
- Analyst Count
- MIST 3
- CNTB 1
- Target Price
- MIST $13.00
- CNTB $8.00
- AVG Volume (30 Days)
- MIST 177.8K
- CNTB 24.6K
- Earning Date
- MIST 11-11-2024
- CNTB 09-05-2024
- Dividend Yield
- MIST N/A
- CNTB N/A
- EPS Growth
- MIST N/A
- CNTB N/A
- EPS
- MIST N/A
- CNTB N/A
- Revenue
- MIST N/A
- CNTB $24,116,000.00
- Revenue This Year
- MIST N/A
- CNTB N/A
- Revenue Next Year
- MIST N/A
- CNTB $63.90
- P/E Ratio
- MIST N/A
- CNTB N/A
- Revenue Growth
- MIST N/A
- CNTB N/A
- 52 Week Low
- MIST $1.12
- CNTB $0.68
- 52 Week High
- MIST $3.52
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- MIST 42.50
- CNTB 44.02
- Support Level
- MIST $1.41
- CNTB $1.18
- Resistance Level
- MIST $1.53
- CNTB $1.26
- Average True Range (ATR)
- MIST 0.07
- CNTB 0.07
- MACD
- MIST -0.01
- CNTB -0.01
- Stochastic Oscillator
- MIST 26.96
- CNTB 13.59
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.